McKesson
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after McKesson beat Q2 e...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organize...
Latest News
3 days ago · seekingalpha.com
McKesson: Slower FY2028 Revenue Growth Makes Today's Premium Less AttractiveMcKesson Corporation maintains a 'Hold' rating as shares trade at a premium, with limited upside to a $1,115 target price. Strong demand for specialty drugs and services drives growth, but GLP-1 coverage expansion is slow and recent acquisitions' synergies will take time. Management raised 2027 adjusted EPS guidance to $45.60–46.40, with consensus and internal forecasts aligned; profit growth expected to outpace revenue.
5 days ago · zacks.com
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending StockRecently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
6 days ago · zacks.com
3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK)McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
10 days ago · marketbeat.com
McKesson Q2 Earnings Call HighlightsMcKesson NYSE: MCK raised its fiscal 2027 adjusted earnings outlook after reporting higher second-quarter revenue and profit, supported by prescription volumes, specialty distribution and demand for medication access services.
11 days ago · zacks.com
McKesson (MCK) Upgraded to Buy: Here's What You Should KnowMcKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
11 days ago · zacks.com
McKesson Corporation (MCK) Hit a 52 Week High, Can the Run Continue?McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
11 days ago · zacks.com
MCK Q2 Earnings Call Highlights Raised Outlook and Specialty GrowthMcKesson raises its fiscal 2027 earnings outlook after strong Q2 results, fueled by specialty drug demand, operating gains and higher-margin healthcare expansion.
12 days ago · zacks.com
MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook RaisedMcKesson's Q2 fiscal 2027 earnings beat estimates on specialty growth and higher prescription volumes, prompting raised guidance despite an after-hours stock dip.
12 days ago · seekingalpha.com
McKesson Corporation (MCK) Q2 2027 Earnings Call TranscriptMcKesson Corporation (MCK) Q2 2027 Earnings Call Transcript
12 days ago · zacks.com
Here's What Key Metrics Tell Us About McKesson (MCK) Q2 EarningsThe headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MCK